Treatment with the immunomodulatory agent lenalidomide prevented IL-10 production by CLL cells, as well as IL-10-induced T-cell dysfunction, by inhibiting activation of the STAT3 pathway. The gene discussed is IL10; the disease is B-cell chronic lymphocytic leukemia.